Baxter International (BAX) Recovery Story Puts Fair Value Back In Focus

Baxter International (BAX) drew fresh attention after recent share moves, with the price closing at $23.37. Investors are weighing mixed return patterns from the past month and past 3 months against improving annual profit metrics.

For context, the Baxter International share price has gained 19.85% year to date, while the 1 year total shareholder return is 6.53% and the 5 year total shareholder return is down 68.29%. This points to recent momentum rebuilding after a prolonged weak stretch.

Scan how Baxter International compares with other beaten-down healthcare names recovering from multi-year slumps in our curated list of 16 high quality undiscovered gems.

For Baxter International, the question now is whether the recent rebound reflects healthier underlying operations or a swing in sentiment around a still challenged story. The answer starts with what the current valuation implies.

Most Popular Narrative: 19% Undervalued

Compared with the last close at $23.37, the most followed narrative pegs Baxter International's fair value at $28.73, implying a discounted price that investors are trying to reconcile with a still loss-making profile.

Normalization of hospital purchasing patterns and patient admissions is expected to drive increased utilization of Baxter's core IV solutions and infusion systems as fluid conservation efforts abate, providing upside to revenue growth and margin expansion as volumes recover.

Baxter's strengthened focus on innovation, including new product launches in advanced infusion systems, AI-enabled devices, and compounding, aligns with growing demand for efficient, digitalized, and connected healthcare equipment, positioning the company to capture higher-margin revenue streams and gain market share.

See why 18 investors see Baxter International as 19% undervalued.

Analysts behind this storyline use an 8.74% discount rate and arrive at fair value of $28.73, which is about 19% above the current share price. That gap rests on forecasts that Baxter International moves from a net loss of $968.0m to earnings of $788.3m by around 2029, while revenue growth remains relatively modest and margins shift from negative territory toward a profit margin of about 6.3%.

The same framework assumes a future P/E multiple of roughly 24.7x on those 2029 earnings, which sits slightly below the current 26.2x level used for the wider US Medical Equipment sector in the narrative. For investors, the key judgment is whether that earnings path and margin repair look achievable enough to justify paying a multiple that expects clearer profitability from a business that is still unprofitable today.

Result: Fair Value of $28.73 (UNDERVALUED)

Still, the story can shift quickly if hospital IV fluid usage remains about 20% below historical patterns, or if quality issues around infusion pumps drag on longer than expected.

Find out about the key risks to this Baxter International narrative.

Next Steps

Mixed signals around Baxter International's recovery story will not settle themselves. Act quickly, review the full picture, and weigh the 4 key rewards and 1 important warning sign.

Looking for more Baxter International investment ideas?

If Baxter International has your attention, do not stop here. Use the Simply Wall St Screener to surface fresh opportunities before other investors catch on.

• Target dependable cash generators by reviewing companies in the 8 dividend fortresses that may suit an income focused approach.
• Hunt for quality at a discount through the 32 high quality undervalued stocks that highlight firms trading below their assessed worth.
• Prioritise resilience first by checking the 30 resilient stocks with low risk scores that emphasise businesses with stronger overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com